In your framing of “aggregate ASCVD risk” as a stimulant to extremely aggressive LDL-C lowering, what clinical signature should compel the general cardiologist to translate the results with alirocumab in ODYSSEY Outcomes to the front lines?

In your framing of “aggregate ASCVD risk” as a stimulant to extremely aggressive LDL-C lowering, what clinical signature should compel the general cardiologist to translate the results with alirocumab in ODYSSEY Outcomes to the front lines?

In your framing of “aggregate ASCVD risk” as a stimulant to extremely aggressive LDL-C lowering, what clinical signature should compel the general cardiologist to translate the results with alirocumab in ODYSSEY Outcomes to the front lines?


Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Medical Cardiology, Interventional Cardiology, Lipid Medicine, Atherosclerosis and Diabetes Specialist's Perspective

Presenter

Christian Ruff, MD

Christian Ruff, MD

Christian Ruff, MD Principal Investigator, ENGAGE-AF Trial TIMI Group Director, General Cardiology Brigham and Women’s Hospital Assistant Professor of Medicine Harvard Medical School Boston, MA